GBA Presents: RADIO SAVANT-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2022.

  1. TESLA BOTTOMED AGAIN TODAY TED !!! :D
    HF SAYS IT'S A GO-! HOLD FOR 1 YEAR<----------------------

    IRA ALERT))))))))))))))))))))))))))))))))))))TSLA

    WE IN THIS MORNING NOT SURE WHERE A FEW BUCKS OFF LOW!!!!

    gba upgrade TSLA!!!!!:caution:
     
    #12161     Jan 6, 2023


  2. GlycoMimetics, Inc. (GLYC)- DO WE LIKE OR NOT?
    NasdaqGM - NasdaqGM Real Time Price.
    2.7950+0.1950(+7.50%)
    As of 02:37PM EST.

     
    #12162     Jan 6, 2023
  3. JUST SOME HOUSEKEEPING HERE.
    WAY BACK IN MARCH WE BOUGHT AEROJET ALL OVER IN MANY ACCOUNTS-AND I HAVE FORGOTTEN --
    THESE GUYS GOT BOUGHT OUT IT'S DEAD MONEY JUST SITTING IN IRA'S-!

    Aerojet Rocketdyne Holdings,

    39.13-0.14(-0.36%) <-- I think it's a buy here
    As of 12:32PM EDT.

    #373 Mar 21, 2022 Report
    Reply Share



    Aerojet Rocketdyne Holdings, Inc. (AJRD)
    NYSE - Nasdaq Real Time Price. Currency in USD

    55.91-0.18(-0.32%)<----------------- RAISE CASH!
    As of 02:55PM EST.
     
    Last edited: Jan 6, 2023
    #12163     Jan 6, 2023
  4. seven years ago... Jimmy is impressed

     
    Last edited: Jan 6, 2023
    #12164     Jan 6, 2023
  5. 4 years ago... Stk is $45.80

     
    #12165     Jan 6, 2023
  6. TODAY- o_O

    Esperion Therapeutics, Inc. (ESPR)
    NasdaqGM - NasdaqGM Real Time Price.
    6.41+0.12(+1.83%)
    As of 03:07PM EST.
     
    #12166     Jan 6, 2023
  7. H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint 12/07 ESPR H.C. Wainwright analyst Joseph Pantginis notes that Esperion has announced its Phase 3 CLEAR Outcomes trial evaluating NEXLETOL met its primary endpoint. Patients experienced a statistically significant risk reduction in MACE-4 after administration of 180 mg/day NEXLETOL compared to placebo. Pantginis expects the announcement to have a positive impact on the stock ahead of the full data, though could see increased volatility in the interim as investors weigh the news. He looks forward to the data at a major medical conference in Q1 2023. The analyst reiterates a Buy rating on the shares with a price target of $22.

    ;)
     
    #12167     Jan 6, 2023
  8. GET UP!
     
    #12168     Jan 6, 2023
  9. WHAT DID I SAY...IT'S ANEW YEAR GET UP..

    GET OUT OF THAT CHAIR... LOOK HOW FAT YOU ARE!

    MOVE!!! YOU NEED A WORKOUT IN THE WORST WAY....

     
    #12169     Jan 6, 2023
  10. YOU ARE COOL!

     
    #12170     Jan 6, 2023